[Advance in therapy of acute rhinitis--comparison of efficacy and safety of xylometazoline in combination xylometazoline-dexpanthenol in patients with acute rhinitis].
BACKGROUND
Acute Rhinitis is based on an inflammation of the nasal mucous membrane with nasal discharge and obstruction. Symptomatic treatment includes local application of decongestants as Xylometazoline and epithelia-protective agents as Dexpanthenol. After proving a synergistic effect of Xylometazoline and Dexpanthenol (Nasic) in patients after nasal surgery, this result should be checked in patients with acute non-allergic rhinitis.


METHODS
Randomised verum controlled double-blind parallel-group-comparison of five days treatment with nasal sprays containing the combination of Xylometazolin-Dexpanthenol or Xylometazolin.


METHODS
The assessments of nasal obstruction, rhinorrhea, hyperplasia of nasal concha and redness of the nasal mucous membrane were defined as main-target parameters.


RESULTS
152 outpatients diagnosed with non-allergic, acute rhinitis were included in this study. 151 patients completed the study according to protocol. The superiority of the treatment with Xylometazolin-Dexpanthenol could be proven for the main outcome measures in comparison to Xylometazolin clinically relevant and statistically significant. The result was also validated by the secondary endpoints. The clinically proven efficacy is emphasized by the rhinoscopic findings and safety parameters showing a better tolerability of the combination.


CONCLUSIONS
Accelerating the wound healing corroborates the superiority of the combination and is due to the epithelia protective effect of Dexpanthenol. These results allow especially under socio-economic points of view the conclusion that shorter treatment time with a diminishing risk of a "rebound effect" will improve compliance.
Kehrl
W
W
Klinik und Ambulatorium für Hals-Nasen-Ohren-Krankenheiten, Katholisches Marienkrankenhaus, Hamburg. Kehrl.hno@marienkrankenhaus.org
Sonnemann
U
U
Dethlefsen
U
U
D000208:Acute Disease; D000281:Administration, Intranasal; D000328:Adult; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D014663:Nasal Decongestants / Q000009:adverse effects / Q000627:therapeutic use*; D015508:Nasal Obstruction / Q000188:drug therapy; D010205:Pantothenic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D012220:Rhinitis / Q000188:drug therapy*; D016896:Treatment Outcome
D004338:Drug Combinations; D007093:Imidazoles; D014663:Nasal Decongestants; D010205:Pantothenic Acid; C007288:dexpanthenol; C009695:xylometazoline
Fortschritt in der Therapie der akuten Rhinitis. Vergleich der Wirksamkeit und Unbedenklichkeit von Xylometazolin mit der Kombination von Xylometazolin-Dexpanthenol bei Patienten mit akuter Rhinitis.